CCTV News: On January 12, the National Health Commission held a press conference. Wang Xiaoyang, deputy director of the Consumer Products Industry Department of the Ministry of Industry and Information Technology, introduced that my country's pharmaceutical industry chain is resilient, has great production capacity, and has great potential for expansion, and has the ability to rapidly increase production on a large scale. In particular, there are a complete range of drugs related to respiratory diseases and large production capacity and output, which can meet related needs.
From the perspective of production and supply, the Ministry of Industry and Information Technology systematically sorted out the production capacity and output of drugs related to respiratory diseases that the public is concerned about, including antipyretic analgesic, antibiotics, Chinese medicine small molecule antiviral drugs, etc. The overall supply is sufficient and the market is stable. For example, oseltamivir phosphate, my country's daily production capacity reaches 1.56 million servings, and its inventory exceeds 47 million servings. Among them, the inventory of granule dosage forms for children exceeds 16 million servings, and the daily production capacity of Lianhua Qingwen reaches 120 million servings, and its inventory exceeds 86 million boxes. The daily production capacity of ibuprofen reaches 150 million tablets, and these categories have the ability to increase and expand production.
